KGAC

K-GAC (K-GAC Life Sciences) is a South Korean biotechnology company specializing in the development of innovative therapeutics and diagnostics based on aminoacyl-tRNA synthetases (AARS). Founded by Professor Kim Sung-hoon, a leading expert in AARS research, the company leverages a proprietary platform to identify novel physiological functions of AARS proteins beyond their traditional role in protein synthesis. K-GAC's pipeline focuses on oncology, particularly targeting difficult-to-treat solid tumors like pancreatic and lung cancer, as well as inflammatory and fibrotic diseases. By targeting the non-canonical activities of AARS, the company aims to develop first-in-class drugs that modulate disease-specific signaling pathways.